ABSTRACT
Good results of the treatment of patients with lower respiratory tract infections with dirithromycin (Eli Lilly, USA), a new semisynthetic macrolide, were recorded. The trial included 15 patients: 6 with acute bronchitis (AB) and 9 with exacerbation of chronic bronchitis (AB) and 9 with exacerbation of chronic bronchitis (ECB). The antibiotic was administered orally in a single dose of 500 mg once a day for 7 days. The treatment efficacy was estimated by the clinical results and laboratory findings. The sputum specimens were investigated bacteriologically with testing the microflora for the drug susceptibility by using the diffusion disks. 50 per cent of the patients with AB isolated Streptococcus viridans with low (the diameter of the growth inhibition zones < 16 mm) and intermediate (16-17 mm) susceptibility to the antibiotic, 33.3 per cent of the patients isolated highly susceptible (19 mm) strains of Str. pneumonia and 16.7 per cent of the patients isolated resistant (15 mm) strains of Staphylococcus epidermidis. Highly susceptible (17-19 mm) strains of Haemophilus influenzae and Str. viridans were isolated respectively from 55.5 and 45.5 per cent of the patients with ECB. In 4 patients with ECB a clinical improvement of the state was recorded. In the other patients with AB and ECB the recovery was stated. The bacteriological tests revealed a new pathogen in 2 patients with ECB and the failure of the treatment in another 2 patients with ECB. In all the other patients the pathogen was shown to be eradicated. In the patients isolating the new pathogen the symptomatic recovery was stated in the posttherapeutic period. Therefore, diritromycin proved to be efficient in 13 out of the 15 patients with lower respiratory tract infections. It should be noted that the drug tolerance was excellent. None of the patients showed any adverse reactions.
